Drug-Eluting Stent Study: How Innovation Changes Care Patterns, Costs
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stents added $1.57 billion in annual Medicare costs in their first four years on the U.S. market, with the largest increases occurring among patients with stable coronary disease, according to observational research published April 25.